SCHEMBL2492516

SCHEMBL2492516

COc1cc(C=CCCC(=O)CC(=O)O)cc(OC)c1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 2/20 0.54
PKM P14618 1/20 0.54
PTGS2 P35354 1/20 0.54
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2B6 P20813 1/20 0.51
ALOX5 P09917 11/20 0.48
STAT3 P40763 2/20 0.47
NFE2L2 Q16236 2/20 0.47
PTGES O14684 1/20 0.47
MET P08581 3/20 0.46
TUBB1 Q9H4B7 1/20 0.46
ABL1 P00519 1/20 0.45
BCR P11274 1/20 0.45
KDM4E B2RXH2 2/20 0.45
GAA P10253 2/20 0.45
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30901848 0.82 CYP3A4 (0.61) PTGS1PKMPTGS2CYP1A2CYP3A4
SCHEMBL1791116 0.81 PTGS1 (0.54) PTGS1PKMPTGS2CYP1A2CYP3A4
SCHEMBL5146748 0.79 PTGS1 (0.63) PTGS1PKMPTGS2CYP1A2CYP3A4
SCHEMBL1788486 0.78 PTGS1 (0.48) PTGS1PKMPTGS2CYP1A2CYP3A4
SCHEMBL2852406 0.75 ALOX5 (0.70) PKMCYP1A2CYP3A4CYP2C9CYP2B6
SCHEMBL13237036 0.72 ALOX5 (0.79) PTGS1PKMPTGS2CYP1A2CYP3A4
SCHEMBL14875131 0.72 ALOX5 (0.79) PTGS1PKMPTGS2CYP1A2CYP3A4
SCHEMBL807443 0.72 ABL1 (0.59) PTGS1PKMPTGS2CYP1A2CYP3A4
SCHEMBL29603846 0.72 ABL1 (0.59) PTGS1PKMPTGS2CYP1A2CYP3A4
SCHEMBL1457517 0.72 ABL1 (0.59) PTGS1PKMPTGS2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580775-B2 Use of derivatives of sinapinic acid and compositions comprising such derivatives COGNIS IP MANAGEMENT GMBH (DE) 2013-11-12 US disclosed
EP-2117499-B1 Use of sinapic acid in non-therapeutic cosmetic and/or topical compositions COGNIS IP MAN GMBH (DE) 2011-10-26 EP disclosed
US-20100130605-A1 Use of Derivatives of Sinapinic Acid and Compositions Comprising Such Derivatives COGNIS IP MANAGEMENT GMBH (DE) 2010-05-27 US disclosed
EP-2117499-A1 USE OF DERIVATIVES OF SINAPINIC ACID AND COMPOSITIONS COMPRISING SUCH DERIVATIVES Cognis IP Management GmbH (DE) 2009-11-18 EP disclosed
WO-2008107093-A1 USE OF DERIVATIVES OF SINAPINIC ACID AND COMPOSITIONS COMPRISING SUCH DERIVATIVES COGNIS IP MANAGEMENT GMBH (DE) 2008-09-12 WO disclosed
EP-1967175-A1 Use of derivatives of sinapinic acid and compositions comprising such derivatives Cognis IP Management GmbH (DE) 2008-09-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130605-A1 Use of Derivatives of Sinapinic Acid and Compositions Comprising Such Derivatives TYR, ASAH1, AANAT PTGS1 449/4885PKM 1859/4885PTGS2 895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.